Ventilation mask

Information

  • Patent Grant
  • 12076485
  • Patent Number
    12,076,485
  • Date Filed
    Monday, January 10, 2022
    2 years ago
  • Date Issued
    Tuesday, September 3, 2024
    2 months ago
Abstract
A nasal mask has exhalation scoop fixed adjacent a lower portion of mask, adapted to overlie an upper lip of a patient when the mask is worn. The mask includes ports for sampling flow of CO2 expelled from the mouth and nose of the patient to the end-tidal CO2 port, and a pressure-based flow resistor for balancing flow of CO2 expelled from the mouth and the nose of the patient.
Description
BACKGROUND OF THE INVENTION

The present invention relates to improvements in anesthesia masks and ventilation masks.


During surgery a patient usually is placed under anesthesia. The most common delivery system consists of canisters containing anesthesia gases and oxygen, a system of regulating the gas flow and the patient's breathing, and a device ensuring the potency of the patient's airway for breathing, oxygenation and the delivery of the anesthetic gas mixture. A ventilation mask is used to provide oxygen to the patient either during emergency and/or elective airway management, which includes but is not limited to: before a patient is anesthetized for surgery; while the patient is sedated during the surgery or procedure; while the patient is recovering from anesthesia; after the patient has recovered from anesthesia; and during any event where a patient requires supplemental oxygen. However, conventional ventilation masks are less than ideal.


Moreover, situations may arise during surgery that require rapid intubation of a patient. Full face masks, i.e. masks covering both the nose and mouth of a patient are problematic in emergency situations since a mask must be removed to uncover the mouth of a patient for intubation. However, removing the mask also removes oxygen support.


In our co-pending PCT Application Serial Nos. PCT/US2014/44934, PCT/US2015/034277 and PCT/US2015/044341 (hereinafter the '934, '277 and '341 PCT applications), we provide improved ventilation/anesthesia masks that overcome the aforesaid and other problems with the prior art by providing, in one aspect, a combination mask comprising a nasal portion or mask and an oral portion or mask defining respectively a nasal chamber and an oral chamber, detachably connected to one another wherein the nasal mask may be used separately or connected to the oral mask as a combination nasal/oral mask. We also provide a nasal mask with one or more ports, and various strap systems for holding the mask on a patient's face. We also provide a nasal only mask with one or more sensors for sensing end-tidal CO2 or other gases, and for scavenging gases. See our co-pending PCT Application Serial No. PCT/US16/037070 (hereafter the '070 PCT application). Such combination nasal/oral masks and nasal only masks are available commercially from Revolutionary Medical Devices, Inc. of Tucson, Arizona, under the trademark SuperNO2VA®.


The present invention provides improvements in nasal masks such as described in our aforesaid PCT applications, by providing an exhalation scoop adjacent the bottom of the nasal mask to overlay at least in part the upper lip of a patient, when the mask is worn. The exhalation scoop may be formed of a flexible, preferably resiliently deformable material, and fixed mechanically or adhesively to the mask. Alternatively, the exhalation scoop may be formed with a lip to fit in a matching groove in the outer surface of the nasal mask, or formed integrally with the mask. The exhalation scoop is flexible so as to permit a surgeon to compress or push the exhalation scoop out of the way to permit access to the patient's mouth, while the nasal mask remains on the patient. Alternatively, the exhalation scoop may be folded back on itself leaving access to the patient's mouth, while the nasal mask remains on the patient.


In one aspect the invention provides a nasal mask having exhalation scoop formed of a the flexible or resiliently deformable material, fixed adjacent a lower portion of mask, adapted to overlie an upper lip of a patient when the mask is worn.


In another aspect the exhalation scoop is adapted to be pressed out of the way to permit access to the mouth of a patient.


In still another aspect the exhalation scoop is adapted to be folded back on itself to permit access to the mouth of a patient.


In yet another aspect, the mask includes an end-tidal CO2 port for sampling exhaled CO2 expelled from a mouth and/or nose of a patient.


In still yet another aspect the mask includes a ventilation port adapted to attach to an anesthesia machine, ventilation machine, hyperinflation bag or other ventilation or gas accessory.


In a still further aspect the mask further includes an oxygen port adapted for connection to an oxygen source for supplying oxygen to an interior of the mask.


In another aspect, the mask has tabs or eyelets for attaching one or more mask straps.


The present invention also provides a method for ventilating a patient, comprising providing a nasal mask having exhalation scoop formed of a the flexible or resiliently deformable material, fixed adjacent a lower portion of mask, and adapted to overlie an upper lip of a patient when the mask is worn, and when needed, moving the exhalation scoop out of the way to provide access to the patient's mouth.


In one aspect of the method the exhalation scoop is pressed out of the way to permit access to the mouth of a patient.


In another aspect of the method the exhalation scoop is folded back on itself to permit access to the mouth of a patient.


In still yet another aspect the method includes providing a nasal mask with a exhalation scoop as described above, and monitoring end-tidal CO2 port by sampling exhaled CO2 expelled from a mouth and/or nose of a patient using an end-tidal CO2 monitor.


In still yet another aspect, the mask is attached to an anesthesia machine, ventilation machine, hyperinflation bag or other ventilation or gas accessory, or to an oxygen source for supplying oxygen to an interior of the mask.


The present invention also provides a nasal mask having an exhalation scoop fixed adjacent a lower portion of the mask, adapted to overly an upper lip of a patient when the mask is worn, wherein said exhalation scoop includes an opening permitting access to a mouth of a patient when the mask is worn, and a flexible flap arranged on an inside surface of the scoop for closing off the opening. In one embodiment, the opening comprises an aperture or one or more slits.


The invention also provides a method for ventilating a patient, comprising providing a nasal mask having an exhalation scoop fixed adjacent a lower portion of the mask and adapted to overly at least in part the mouth of the patient when a mask is worn, wherein the exhalation scoop includes an aperture permitting access to the mouth of the patient, and accessing the mouth of the patient by pushing a functional tool through the aperture.


In one embodiment, the tool is removed, the aperture is essentially closed by the flap.


Also provided is a nasal mask having an exhalation scoop fixed adjacent a lower portion of the mask, adapted to overly the mouth of a patient, at least in part, when the mask is worn, said mask further including an end-tidal CO2 port for sampling exhaled CO2 expelled from a mouth and nose of the patient, wherein said end-tidal CO2 port is further provided with an interface for connecting with an interface connector.


In one embodiment, the interface connector comprises a luer lock interface connector. Finally, the invention provides a method for ventilating a patient, comprising providing a nasal mask as above described, and introducing a fluid into the interior of the mask through the interface connector.


In one embodiment, the fluid comprises a sedative such as lidocaine.


In another embodiment, the fluid added through the interface connector is mixed with gases within the mask.


In yet another embodiment, the present invention provides improvements over the nasal mask as described above, and having oral and nasal CO2 sampling ports, by providing a mechanism for substantially balancing flow between the oral and nasal CO2 sampling ports of the mask.


More particularly, the present invention provides a pressure-based flow resistor located inside the nasal chamber of the mask for maintaining substantially constant flow between the nasal and oral sampling openings by varying resistance as a function of differential pressure between the nasal and oral chambers.


In one aspect of the invention there is provided a nasal mask having an exhalation scoop fixed adjacent a lower portion of mask, adapted to overlie an upper lip of a patient when the mask is worn, said mask including first port for sampling exhaled CO2 expelled from a mouth of the patient, and a second port for sampling exhaled CO2 expelled from a nose of a patient, said mask further including a pressure-based flow resistor communicating with said second post adapted to maintain substantially constant sampling flow of CO2 expelled from the mouth and nose of the patient to the end-tidal CO2 port.


In still another embodiment the pressure-based flow resistor maintains constant flow by maintaining constant flow by varying resistance as a function of differential pressure, between the first port and the second port, QBC, as defined by (PB−PC)1/2/RBC.


In another aspect, the pressure-based flow resistor comprises a manifold having two or more holes which communicated between a nasal chamber of the mask and an end tidal CO2 port, and flow occurs due to differential pressure between the nasal chamber and the end-tidal CO2 port.


In yet another aspect the manifold comprises a flexible membrance that deflects as a function of pressure and varies the flow resistance to the end tidal CO2 port. In such aspect the deflection amount, δZ, preferably varies with resistance RBC, in proportion to the differential pressure PB−PC.


In another aspect the maximum flow resistance is defined by a geometry of a hole in the membrane that is not blocked by the membrane due to a central opening n the membrane.


In still another aspect the membrane blocks flow to one or more holes in the membrane when pressure deflects the membrane in the Z direction.


The present invention also provides a method for ventilating a patient, comprising providing a nasal mask having an exhalation scoop fixed adjacent a lower portion of mask, adapted to overlie an upper lip of a patient when the mask is worn, said mask including first port for sampling exhaled CO2 expelled from a mouth of the patient, and a second port for sampling exhaled CO2 expelled from a nose of a patient, said mask further including a pressure-based flow resistor communicating with said second post adapted to maintain substantially constant sampling flow of CO2 expelled from the mouth and nose of the patient to the end-tidal CO2 port, and connecting the sampling flow to an end-tidal CO2 port.


In another aspect of the method the pressure-based flow resistor maintains constant flow by maintaining constant flow by varying resistance as a function of differential pressure, between the first port and the second port, QBC, as defined by (PB−PC)1/2/RBC.


In still yet another aspect of the method the pressure-based flow resistor comprises a manifold having two or more holes which communicate between a nasal chamber of the mask and an end tidal CO2 port, and flow occurs due to differential pressure between the nasal chamber and the end-tidal CO2 port.


In yet another aspect of the method the manifold comprises a flexible membrane that deflects as a function of pressure and varies the flow resistance to the end tidal CO2 port. In such aspect the deflection amount, δZ, preferably varies with resistance RBC, in proportion to the differential pressure PB−PC.


In still yet another aspect of the method the maximum flow resistance is defined by a geometry of a hole in the membrane that is not blocked by the membrane due to a central opening n the membrane.


In yet another aspect of the method the membrane blocks flow to one or more holes in the membrane when pressure deflects the membrane in the Z direction.





Further features and advantages of the present invention will be seen from the following detailed description, taken in conjunction with the accompanying, wherein



FIGS. 1A-1D are front, rear, top and perspective views respectively, of a nasal mask incorporating an exhalation scoop in accordance with a first embodiment of the present invention;



FIG. 2 is a perspective view showing nasal mask with an exhalation scoop in accordance with the present invention on a patient;



FIG. 3 is a view similar to FIG. 2, showing the exhalation scoop compressed or pushed out of the way to provide oral access;



FIG. 4 is a view similar to FIG. 2, showing a nasal mask with an exhalation scoop folded out of the way to provide oral access;



FIG. 5 is a perspective view of a nasal mask with an exhalation scoop showing an alternative method of gaining access to the mouth in accordance with a second embodiment of the present invention;



FIG. 6 is a view similar to FIG. 5 showing how oral access is achieved using the exhalation scoop of FIG. 5;



FIG. 7 is a view similar to FIG. 5 of a third embodiment of the invention;



FIGS. 8A, 8B and 8C are perspective views similar to FIG. 2 of yet another and fourth embodiment of the invention;



FIG. 9 is a side elevational view, in cross section, of the CO2 sampling port of the FIG. 2 mask;



FIG. 10 is a side elevational view, in cross section, of the mask in FIG. 2;



FIG. 11 is a fluid flow schematic in accordance with the FIG. 2 mask;



FIG. 12A is a perspective view, from the inside, of a mask in accordance with a preferred embodiment of the present invention;



FIG. 12B is an enlarged view of a flexible seal flap valve of the nasal mask of FIG. 12A;



FIG. 12C is a side elevational view, in cross section, of the nasal mask of FIG. 12A;



FIG. 13A is a side elevational view, in cross section, of the seal of FIG. 12B in an open position; and



FIG. 13B is a view, similar to FIG. 13A, of the seal flap valve of FIG. 13A.





As used herein “nasal mask” preferably comprises a nasal mask similar to the nasal mask such as described in our aforesaid '934, '277, '341, and '070 PCT Applications including in particular a SuperNO2VA® nasal mask available commercially from Revolutionary Medical Devices, Inc. of Tucson, Arizona.



FIGS. 1A-1D are front, rear, top and perspective views of a nasal mask 10 somewhat similar to the nasal mask described in FIGS. 16A-16E our aforesaid PCT Application No. PCT/US16/37070, but having an exhalation scoop 12 formed of a flexible, preferably resiliently deformable material, fixed to a lower portion 14 of the mask. Exhalation scoop 12 preferably has a 00 Durometer Hardness of 0020 to 0050, to a Shore A Hardness of 2-10, more preferably a Shore A Hardness of 3-7, most preferably a Shore A Hardness of about 5. The softer the material the better.


Referring also to FIG. 2, the mask 10 also includes a gas sampling device (shown in phantom at 16) adapted for suction attached to an end-tidal (“ET”) CO2 port 18 and adapted for drawing gas samples from both the oral and nasal exhalations of the patient. One opening 20 of the EtCO2 manifold is located behind the exhalation scoop 12 to overlie the upper lip of a patient, when the mask is worn by a patient, on the exterior of the nasal mask 10, where a negative pressure (pressure less than atmospheric pressure) is created by a gas sampling device 16. A second opening 22 of the manifold is located to underlie the nares of the patient, on the interior of the nasal mask where a negative pressure is also created by the gas sampling device 16. When the patient exhales, oral and nasal exhalation are collected through openings 20, 22 and proceed through the manifold and exit the EtCO2 port that is connected to the gas sampling device 16 that provided the negative pressure. Concentration levels of the gas, such as CO2 are then measured by gas sampling device 16.


The nasal mask interior chamber is pressurized through a ventilation port 23 by an anesthesia machine or another ventilation device (shown in phantom at 24). Flow from the patient's nose is drawn to the negative pressure of the opening of the manifold interior of the nasal chamber. The patient's mouth is at atmospheric pressure and the flow of the oral exhalation is channeled by the exhalation scoop where it is drawn by the negative pressure presented by gas sampling system through the manifold opening. Samples of both the nasal and oral exhalation flow through a manifold, and exit the EtCO2 port 18 to the gas sampling device 16. The mask 10 also includes an oxygen port 25 for supplying oxygen from an oxygen source (shown in phantom at 27) to a patient.


One benefit of the flexible exhalation scoop design is that if the surgeon requires access to the patients mouth to employ a device such as an intubation tube or endoscope 26, the exhalation scoop 12 can be flexed or pushed by the device in the nominal “y” direction, providing access to the patient's mouth as shown in FIG. 3.


Another benefit of one flexible exhalation scoop 12 design is that if the surgeon requires access to the patient's mouth, there exists a bi-stable condition where the scoop 12 overlies the upper lip and/or mouth of the patient, as shown in FIG. 2, or the scoop 12 can be folded over itself about the nominal “X” axis and remain stable with the scoop 12 no longer covering the mouth as shown in FIG. 4. This allows access to the patient's mouth as shown, and nasal Et CO2 can still be collected. Once the endoscope 26 or other device is removed from the patient's mouth, should the clinician decide to continue collecting oral Et CO2 samples, the flexible exhalation scoop 12 can be unfolded about the “X” axis, again covering the patient's mouth as in FIG. 2.


Completing the nasal mask are tabs and/or eyelets 30 for attaching one or more head straps (not shown).


Referring to FIGS. 5 and 6, in an alternative embodiment of the invention, the exhalation scoop 12A includes a circular aperture 50 covered by a flap 52 attached to the inside of the exhalation scoop 12A at anchor 54. Exhalation scoop 12A is similar in shape to the exhalation scoop 12 of FIGS. 1-4, but need not be made of as flexible materials. Flap 52 and anchor 54 are shown in phantom since they are on the inside of scoop 12A. Flap 50 is in a normally closed position, and is held against the inside surface of scoop 12A by positive pressure within the mask, when the mask is worn by a patient.



FIG. 6 shows a functional device such as an intubation tube or endoscope 26 inserted through aperture 50, pushing flap 52 aside whereby to permit access to the patient's mouth, while permitting continual end-tidal sampling, etc. Flap 50 is flexible so as to substantially seal around the functional device. When the functional tool 26 is removed, the aperture 50 is again sealed by flap 50.


In another embodiment, shown in FIG. 7, aperture 50 is replaced by a slip 70 which is backed by flexible flap 72 anchored at 74 to the inside of the exhalation scoop 12B. Similar to port 50, slit 70 permits insertion of a functional device through the exhalation scoop, giving access to the patient's mouth, while leaving the exhalation scoop in place so as to permit continued end-tidal CO2 sampling, etc.


Note with respect to the embodiments of FIGS. 5-6 and 7, any geometric shape may be used for the aperture, the slits and the flap so as to permit passage of a laryngoscope, endotracheal tube, endoscope or other functional device to pass through the exhalation scoop, while leaving the exhalation scoop in place for continued end-tidal CO2 monitoring, etc. Due to the flexibility of the flap, the flap essentially seals around the functional tool and allows for continued collection of orally expelled CO2. When the tool is removed from the scoop, the flap again closes off the aperture or slits.


Yet another embodiment of the invention is shown in FIGS. 8A-8C. In this latter embodiment, the Et CO2 port has a luer connection 80, thus providing the Et CO2 port the ability to interface with other devices, having a luer interface connection 82 such as a syringe 84. Thus, the Et CO2 port can be utilized to deliver fluids, or gases, including sedatives such as lidocaine, contained in a syringe. FIGS. 8A-8B show a fluid-filled syringe 84 being connected to the Et CO2 port and FIG. 8C shows the syringe 84 being compressed, with the fluid being expelled into the interior of the mask. Gasses, such as O2, that flow through either the O2 port, the ventilation port 86, or both, will mix with the expressed fluid, nebulizing it where it is then inhaled by the patient.


Referring again to FIG. 2, as noted supra, mask 10 also includes a gas sampling device (shown in phantom at 16) in the form of suction attached to an end-tidal (“ET”) CO2 port 18 and adapted for drawing gas samples from both the oral and nasal exhalations of the patient. One opening 20 of the EtCO2 manifold is behind the exhalation scoop 12 to overlie the upper lip of a patient, when the mask is worn by a patient, on the exterior of the nasal mask 10, where a negative pressure (pressure less than atmospheric pressure) is created by gas sampling device 16. A second opening 22 of the manifold is below the nares on the interior of the nasal mask where a negative pressure is also created by the gas sampling device 16. When the patient exhales, oral and nasal exhalation are collected through openings 20, 22 and proceed through the manifold and exit the EtCO2 port that is connected to the gas sampling device 16 that provided the negative pressure. Concentration levels of the gas, such as CO2 are then measured by gas sampling device 16.


Referring also to FIGS. 9-11, in use oral exhalation enters the CO2 port through a single opening, hole 20, and nasal exhalation enters the CO2 port through a single opening, hole 30, as shown in FIG. 2. The CO2 port is connected to a CO2 monitoring device that creates suction, collecting the exhalation sample by a sampling line. The mask operates in an unpressurized configuration here oxygen is supplied through the O2 port 25 and the ventilation port 23 is open to the atmosphere where both the oxygen and exhalation of CO2 escape, as well as a pressurized configuration where the oxygen enters the mask through the ventilation port and also, optionally, the oxygen port. Exhalation of the CO2 and oxygen then exits through the ventilation port 23 that is connected to either an anesthesia machine, a ventilator, a CPAP machine or a ventilation bag such as one on a hyperinflation system.


Volumetric flow through a pipe, Q, is governed by the fluid dynamic laws shown in

Equations 1-5.
Q=πϕ2V/4  Eq. 1
ΔP=ρfLV2/2ϕ  Eq. 2
ΔP=(8ρfL/π2ϕ5)Q2  Eq. 3
R2=(8ρfL/π2ϕ5)  Eq. 4
Q=ΔP1/2R  Eq. 5

wherein:


Q=Volumetric flow rate (m3/min)


ρ=fluid density (kg/m3)


ϕ=pipe diameter (m)


V=fluid velocity (m/min)


ΔP=Differential pressure between two points (Pa)


f=friction factor for pipe


L=pipe length (m)


R=pipe resistance (Pa1/2-min/m3)


The fluid flow model for the current mask 10 shown in FIGS. 2 and 9-11 has 4 node points with respective pressure and flow rates defined as follows:


Node point A, Entrance of hole 20 that is the oral opening into the CO2 Port.






    • Hole 20 diameter, ϕaCO2 Port

    • Pressure at hole 20, PA

    • Volumetric oral exhalation flow through hole 20, QAC

    • Pipe resistance from Node A to Node C, RAC

    • Length of pipe from Node A to Node C, LAC

      Node point B, Entrance of hole 22 that is the nasal opening into the CO2 Port.

    • Hole 22 diameter, ϕb

    • Pressure at hole 22, PB

    • Volumetric nasal exhalation flow through hole 22, QBC

    • Pipe resistance from Node B to Node C, RBC

    • Length of pipe from Node B to Node C, LBC

      Node point C, Interior of CO2 Port adjacent to exit of hole 22 into CO2 Port

    • CO2 Port diameter, ϕCO2 Port

    • Pressure at Node C, PC

    • Volumetric flow through Node C, QCD

    • Pipe resistance from Node C to Node D, RCD

    • Length of pipe from Node C to Node D, LCD

      Node point D, Exit of CO2 Port (Connects to CO2 Sample line)

    • CO2 Port diameter, ϕCO2 Port

    • Pressure at Node D, PD

    • Volumetric flow through Node D, QCD

      Flow between each of the Node points is defined as follows:

      QAC+QBC=QCD  Eq. 6
      QAC=(PA−PC)1/2/RAC  Eq. 7
      QBC=(PB−PC)1/2/RBC  Eq. 8
      QCD=(PC−PD)1/2/RCD  Eq. 9





Ideally, the flow from the oral and nasal exhalation, QAC and QBC, are equal in order to measure exhaled CO2. In an unpressurized configuration, PA and PB are both approximately equal and equal to the atmospheric pressure. In such configuration, the associated resistance between nodes, RAC and RBC would be designed to be equal by properly configuring the associated pipe diameters and pipe lengths. The challenge is that in a pressurized configuration, the nasal portion of the mask, PB, is pressurized to a nominal value of 10-15 CM H2O relative to the atmosphere and PA. In such configuration, RBC will need to be proportionally larger than RAC in order to have QAC equal QBC. If RBC were not increased, the QBC would be larger than QAC. In order to maintain substantially equal oral and nasal flow for CO2 sampling for both the unpressurized and pressurized configurations, RBC must vary as a function of PB in order to maintain equal flow.


As used herein the terms “substantially balancing flow” and “substantially constant flow” are used interchangeably, and mean a flow of within about volume 10%, preferably within about volume 5%, more preferably within about volume 2-3%.


A preferred embodiment of a pressure-based flow resistor is illustrated in FIGS. 12A-12C. In this embodiment, the nasal mask 100, which is similar to mask 10 described above, includes a manifold 102 with two or more holes 104, 106 connecting nasal chamber of the mask to a CO2 port 18. Referring also to FIGS. 13A and 13B a membrane disk 112 having an opening 114 is aligned over a hole 116 which covers the manifold 102 where under a given pressure, PB, nasal exhalation can travel through the hole 114 of the manifold, hole 116, as well as a hole 118 into the CO2 port 18. As pressure increases, to PBCrit, the membrane disk 112 deflects in the Z direction by moving up by a distance δZ. At that point, flow from the nasal chamber 11 to hole 118 is blocked and can only travel through hole 116. As a result, flow resistance from the nasal chamber 11 to the CO2 port 18 RBC, is increased. Hole 118 and hole 116 geometry can be selected so that when the membrane disc 112 has deflected an amount less than δZ, the flow, ZBC, as defined by (PB−PC)1/2/RBC is nominally constant and made substantially equal to Om from Oral exhalation. As a result, sampling flow is substantially equalized.


Various changes may be made in the above without departing from the spirit and scope of the invention.

Claims
  • 1. A nasal mask comprising: an inner surface forming a nasal chamber;a ventilation port that extends from an upper portion of the nasal mask in a first direction;an end-tidal CO2 port that extends from the upper portion of the nasal mask and comprises an opening adjacent a lower portion of the nasal mask; andan exhalation scoop fixed adjacent the lower portion of the nasal mask and adapted to overlie an upper lip of a patient when the nasal mask is worn;wherein the opening is located behind the exhalation scoop for sampling CO2 expelled from a mouth of the patient, and the exhalation scoop is formed of a material that is flexible relative to a material that defines the nasal chamber such that the exhalation scoop is adapted to be folded back in the first direction toward the nasal chamber to permit access to the mouth of the patient.
  • 2. The nasal mask of claim 1, wherein the end-tidal CO2 port extends from the upper portion of the nasal mask in the first direction.
  • 3. The nasal mask of claim 1, wherein the end-tidal CO2 port comprises another opening located in the nasal chamber to underlie a nare of the patient for sampling exhaled CO2 expelled from a nose of the patient.
  • 4. The nasal mask of claim 1, wherein the ventilation port is configured to connect with any of an anesthesia machine, a ventilation machine, or a hyperinflation bag.
  • 5. The nasal mask of claim 1, further comprising an oxygen port configured to connect with an oxygen source for supplying oxygen to the nasal chamber.
  • 6. The nasal mask of claim 5, wherein the oxygen port extends from the upper portion of the nasal mask in the first direction.
  • 7. The nasal mask of claim 1, wherein the material of the exhalation scoop is formed of a material having a Shore 00 Durometer Hardness of 0020 to 0050.
  • 8. The nasal mask of claim 1, wherein the material of the exhalation scoop is formed of a material having a Shore A Hardness selected from 2-10 or 3-7.
  • 9. The nasal mask of claim 1, further comprising a groove in an outer surface of the nasal mask, wherein the exhalation scoop comprises a lip configured to fit in the groove.
  • 10. The nasal mask of claim 1, wherein the exhalation scoop is integrally formed with the nasal mask.
  • 11. The nasal mask of claim 1, wherein the exhalation scoop is configured to be folded around an axis that extends in a second direction, and wherein the second direction is transverse relative to the first direction.
  • 12. A method for ventilating a patient, comprising: providing a nasal mask having an inner surface forming a nasal chamber, a ventilation port that extends from an upper portion of the nasal mask in a first direction, an end-tidal CO2 port that extends from the upper portion of the nasal mask and comprises an opening adjacent a lower portion of the nasal mask, and an exhalation scoop fixed adjacent the lower portion of the nasal mask and adapted to overlie an upper lip of the patient when the nasal mask is worn, such that the opening is located behind the exhalation scoop;connecting the ventilation port to any of an anesthesia machine, a ventilation machine, or a hyperinflation bag;folding the exhalation scoop back in the first direction toward the nasal chamber to permit access to a mouth of the patient; andmonitoring end-tidal CO2 by sampling exhaled CO2 expelled from the mouth of the patient into the opening.
  • 13. The method of claim 12, monitoring end-tidal CO2 by sampling CO2 expelled from a nare of the patient into another opening of the end-tidal CO2 port located in the nasal chamber.
  • 14. The method of claim 12, further comprising connecting an oxygen port of said nasal mask to an oxygen source for supplying oxygen to the nasal chamber of the nasal mask.
  • 15. The method of claim 12, wherein folding the exhalation scoop back in the first direction comprises folding the exhalation scoop around an axis that extends in a second direction, and wherein the second direction is transverse relative to the first direction.
  • 16. The method of claim 12, further comprising unfolding the exhalation scoop in a second direction away from the nasal chamber to permit access to the mouth of the patient, wherein the second direction is opposite to the first direction.
  • 17. The method of claim 12, further comprising connecting the end-tidal CO2 port of the nasal mask to a gas sampling device.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/333,215 filed Mar. 13, 2019, which issued as U.S. Pat. No. 11,298,492 on Apr. 12, 2022, which claims priority from PCT Patent Application Serial No. PCT/2017/048046, filed Aug. 22, 2017, which claims priority from U.S. Provisional Application Ser. No. 62/510,192, filed May 23, 2017, and from U.S. Provisional Application Ser. No. 62/467,808, filed Mar. 6, 2017 and from U.S. Provisional Application Ser. No. 62/425,371, filed Nov. 22, 2016 and from U.S. Provisional Application Ser. No. 62/394,405, filed Sep. 14, 2016, the disclosure of each of which is incorporated herein by reference in its entirety.

US Referenced Citations (384)
Number Name Date Kind
1050621 Ford Jan 1913 A
1131802 Stenshoel Mar 1915 A
1441817 McCullough Jan 1923 A
1729525 Stenshoel Sep 1929 A
1776167 Stenshoel Sep 1930 A
2452816 Wagner Nov 1948 A
2843121 Hudson Jul 1958 A
2939458 Lundquist Jun 1960 A
3013556 Galleher Dec 1961 A
3522612 Palmer Aug 1970 A
3556097 Wallace Jan 1971 A
3799164 Rollins Mar 1974 A
3815596 Keener et al. Jun 1974 A
3856051 Bain Dec 1974 A
3889668 Ochs et al. Jun 1975 A
3897777 Morrison Aug 1975 A
D242490 Belkin Nov 1976 S
4005499 Klein Feb 1977 A
4007737 Paluch Feb 1977 A
4015598 Brown Apr 1977 A
4188946 Watson et al. Feb 1980 A
D256161 Oliver Jul 1980 S
4231363 Grimes Nov 1980 A
4232667 Chalon et al. Nov 1980 A
4248218 Fischer Feb 1981 A
4259757 Watson Apr 1981 A
4265235 Fukunaga May 1981 A
4265239 Fischer, Jr et al. May 1981 A
4275720 Wichman Jun 1981 A
4328797 Rollins May 1982 A
4457026 Morris Jul 1984 A
4463755 Suzuki Aug 1984 A
4471769 Lockhart Sep 1984 A
4574796 Lundstrom Mar 1986 A
4596246 Lyall Jun 1986 A
4657010 Wright Apr 1987 A
4677977 Wilcox Jul 1987 A
4700691 Tari et al. Oct 1987 A
4770169 Schmoegner et al. Sep 1988 A
4895172 Lindkvist Jan 1990 A
4905712 Bowlin et al. Mar 1990 A
5046200 Feder Sep 1991 A
5046491 Derrick Sep 1991 A
5121746 Sikora Jun 1992 A
D333404 Thompson Feb 1993 S
5243971 Sullivan et al. Sep 1993 A
5255303 DiMaio et al. Oct 1993 A
5271390 Gray et al. Dec 1993 A
5284160 Dryden Feb 1994 A
D347494 Mustelier May 1994 S
D354128 Rinehart Jan 1995 S
5404873 Leagre et al. Apr 1995 A
5462050 Dahlstrand Oct 1995 A
5474060 Evans Dec 1995 A
5485837 Solesbee et al. Jan 1996 A
5524639 Lanier et al. Jun 1996 A
D373921 Palomo et al. Sep 1996 S
5557049 Ratner Sep 1996 A
RE35339 Rapoport Oct 1996 E
5560354 Berthon-Jones et al. Oct 1996 A
5586551 Hilliard Dec 1996 A
5647357 Barnett et al. Jul 1997 A
5649331 Wilkinson et al. Jul 1997 A
5660174 Jacobelli Aug 1997 A
5661859 Schaefer Sep 1997 A
5685298 Idris Nov 1997 A
5738094 Hoftman Apr 1998 A
5746201 Kidd May 1998 A
5749358 Good et al. May 1998 A
5778872 Fukunaga et al. Jul 1998 A
D402755 Kwok Dec 1998 S
5884624 Barnett et al. Mar 1999 A
5933886 Washington Aug 1999 A
5966763 Thomas et al. Oct 1999 A
5975079 Hellings et al. Nov 1999 A
5983896 Fukunaga et al. Nov 1999 A
6003511 Fukunaga et al. Dec 1999 A
6019101 Cotner et al. Feb 2000 A
6035852 Hoftman Mar 2000 A
6058933 Good et al. May 2000 A
D428987 Kwok Aug 2000 S
6112746 Kwok et al. Sep 2000 A
6123071 Berthon-Jones et al. Sep 2000 A
6129082 Leagre Oct 2000 A
6135109 Blasdell et al. Oct 2000 A
6152137 Schwartz et al. Nov 2000 A
D435650 Kwok Dec 2000 S
6155986 Brydon et al. Dec 2000 A
6192886 Rudolph Feb 2001 B1
6216691 Kenyon et al. Apr 2001 B1
6263874 LeDez et al. Jul 2001 B1
6342040 Starr et al. Jan 2002 B1
6357441 Kwok et al. Mar 2002 B1
6397847 Scarberry et al. Jun 2002 B1
6401713 Hill et al. Jun 2002 B1
6412487 Gunaratnam et al. Jul 2002 B1
6412488 Barnett et al. Jul 2002 B1
6439230 Gunaratnam et al. Aug 2002 B1
6439231 Fukunaga et al. Aug 2002 B1
6446288 Pi Sep 2002 B1
6459923 Plewes et al. Oct 2002 B1
6463931 Kwok et al. Oct 2002 B1
6467483 Kopacko et al. Oct 2002 B1
D467345 Gingles et al. Dec 2002 S
6513526 Kwok et al. Feb 2003 B2
6520182 Gunaratnam et al. Feb 2003 B1
6581602 Kwok Jun 2003 B2
6584977 Serowski Jul 2003 B1
6612306 Mault Sep 2003 B1
6615835 Cise Sep 2003 B1
6626178 Morgan et al. Sep 2003 B2
6645835 Cise Sep 2003 B1
6631713 Christopher Oct 2003 B1
6631718 Lovell Oct 2003 B1
6634358 Kwok et al. Oct 2003 B2
6651663 Barnett et al. Nov 2003 B2
6694973 Dunhao et al. Feb 2004 B1
6701927 Kwok et al. Mar 2004 B2
6729333 Barnett et al. May 2004 B2
6736139 Wix May 2004 B1
D493523 Barnett et al. Jul 2004 S
6779524 Strawder et al. Aug 2004 B2
6792943 Kumar et al. Sep 2004 B2
6796308 Gunaratnam et al. Sep 2004 B2
6805117 Ho et al. Oct 2004 B1
6832610 Gradon et al. Dec 2004 B2
6863071 Annett et al. Mar 2005 B2
6871649 Kwok et al. Mar 2005 B2
6892729 Smith et al. May 2005 B2
6895965 Scarberry et al. May 2005 B2
6931664 Chen Aug 2005 B1
6935337 Virr et al. Aug 2005 B2
6981503 Shapiro Jan 2006 B1
7004168 Mace et al. Feb 2006 B2
7007696 Palkon et al. Mar 2006 B2
7013896 Schmidt Mar 2006 B2
7017576 Olsen et al. Mar 2006 B2
7021311 Gunaratnam et al. Apr 2006 B2
7028981 Horton Apr 2006 B2
7036508 Kwok May 2006 B2
7047971 Ho et al. May 2006 B2
7066179 Eaton et al. Jun 2006 B2
7069932 Eaton et al. Jul 2006 B2
7069933 Kwok et al. Jul 2006 B2
7114498 Nashed Oct 2006 B1
7159587 Drew et al. Jan 2007 B2
7178524 Noble Feb 2007 B2
7178527 Kwok et al. Feb 2007 B2
7210481 Lovell et al. May 2007 B1
7219669 Lovell et al. May 2007 B1
7237551 Ho et al. Jul 2007 B2
7243651 Kwok et al. Jul 2007 B2
7287528 Ho et al. Oct 2007 B2
7341060 Ging et al. Mar 2008 B2
7383839 Porat et al. Jun 2008 B2
7445602 Yamamori Nov 2008 B2
7448386 Ho et al. Nov 2008 B2
7467431 Weedling et al. Dec 2008 B2
7487772 Ging et al. Feb 2009 B2
7487777 Gunaratnam et al. Feb 2009 B2
7500280 Dixon et al. Mar 2009 B2
7500482 Biederman Mar 2009 B2
7614398 Virr et al. Nov 2009 B2
7631644 Ho et al. Dec 2009 B2
7665464 Kopacko et al. Feb 2010 B2
7669599 Gunaratnam et al. Mar 2010 B2
7700129 Ito et al. Apr 2010 B2
7743767 Ging et al. Jun 2010 B2
7753051 Burrow et al. Jul 2010 B2
7779832 Ho Aug 2010 B1
7841988 Yamamori Nov 2010 B2
7870859 Barnett et al. Jan 2011 B2
7874292 Smith et al. Jan 2011 B2
7913337 Masson Mar 2011 B1
7926487 Drew et al. Apr 2011 B2
7927285 Yamamori Apr 2011 B2
7931024 Ho et al. Apr 2011 B2
7938117 Chiesa et al. May 2011 B2
7950392 Kwok et al. May 2011 B2
7975694 Ho Jul 2011 B2
7997267 Ging et al. Aug 2011 B2
8001968 Doty et al. Aug 2011 B2
8001970 King et al. Aug 2011 B2
8028699 Ho et al. Oct 2011 B2
8042539 Chandran et al. Oct 2011 B2
8042541 Amarasinghe et al. Oct 2011 B2
8056561 Kwok et al. Nov 2011 B2
8132270 Lang et al. Mar 2012 B2
8161971 Jaffe Apr 2012 B2
8191553 Haworth et al. Jun 2012 B2
8210181 Gunaratnam et al. Jul 2012 B2
8261745 Chandran et al. Sep 2012 B2
8261746 Lynch et al. Sep 2012 B2
8267091 Smith et al. Sep 2012 B2
8302224 Lehman Nov 2012 B2
8312883 Gunaratnam et al. Nov 2012 B2
8336142 See et al. Dec 2012 B1
8336549 Nashed Dec 2012 B2
8347889 Farnum Jan 2013 B2
8365734 Lehman Feb 2013 B1
8397724 Sher et al. Mar 2013 B2
D681383 Derman et al. May 2013 S
8443807 McAuley et al. May 2013 B2
8485190 Barnett et al. Jul 2013 B2
8485192 Davidson et al. Jul 2013 B2
8490623 Berthon-Jones et al. Jul 2013 B2
RE44453 Virr et al. Aug 2013 E
8479726 McAuley Sep 2013 B2
8522783 Kwok et al. Sep 2013 B2
8528558 Drew et al. Sep 2013 B2
8550081 Davidson et al. Oct 2013 B2
8550082 Davidson et al. Oct 2013 B2
8550083 Davidson et al. Oct 2013 B2
8555885 Davidson et al. Oct 2013 B2
8567402 Gunaratnam et al. Oct 2013 B2
8567404 Davidson et al. Oct 2013 B2
D693603 Esquivel et al. Nov 2013 S
8573211 Ho et al. Nov 2013 B2
8573212 Lynch et al. Nov 2013 B2
8573213 Davidson et al. Nov 2013 B2
8573214 Davidson et al. Nov 2013 B2
8573215 Davidson et al. Nov 2013 B2
8573217 Todd et al. Nov 2013 B2
8578935 Davidson et al. Nov 2013 B2
8578939 Kimani Mwangi et al. Nov 2013 B1
8613280 Davidson et al. Dec 2013 B2
8613281 Davidson et al. Dec 2013 B2
8616211 Davidson et al. Dec 2013 B2
8631792 Ho et al. Jan 2014 B2
8636006 Kwok et al. Jan 2014 B2
8667965 Gunaratnam et al. Mar 2014 B2
8684004 Eifler Apr 2014 B2
8689366 Ho Apr 2014 B2
8707950 Rubin Apr 2014 B1
8714157 McAuley et al. May 2014 B2
8752551 Chandran et al. Jun 2014 B2
8807134 Ho et al. Aug 2014 B2
8807135 Worboys et al. Aug 2014 B2
8813748 Kwok et al. Aug 2014 B2
8881728 Sher et al. Nov 2014 B2
8915861 Yamamori et al. Dec 2014 B2
8939151 McAuley et al. Jan 2015 B2
8944061 D'Souza et al. Feb 2015 B2
D726303 Rollins Apr 2015 S
9010330 Barlow et al. Apr 2015 B2
9010331 Lang et al. Apr 2015 B2
9022029 Varga et al. May 2015 B2
9027556 Ng et al. May 2015 B2
9138169 Beard Sep 2015 B2
9186474 Rollins Nov 2015 B1
9295799 McAuley et al. Mar 2016 B2
9295800 Davidson et al. Mar 2016 B2
D753287 Darab Apr 2016 S
D753816 Beard Apr 2016 S
9375545 Darkin et al. Jun 2016 B2
9629975 Pedro Apr 2017 B1
9981104 Groll May 2018 B1
11298492 Pedro Apr 2022 B2
11331446 Pedro May 2022 B2
11813402 Pedro Nov 2023 B2
20010031929 O'Toole Oct 2001 A1
20020017300 Hickle et al. Feb 2002 A1
20020074001 Kwok et al. Jun 2002 A1
20020174868 Kwok et al. Nov 2002 A1
20030024533 Sniadach Feb 2003 A1
20030145859 Bohn et al. Aug 2003 A1
20030183232 Fukunaga et al. Oct 2003 A1
20040069306 Moenning Apr 2004 A1
20040221850 Ging et al. Nov 2004 A1
20050028811 Nelson et al. Feb 2005 A1
20050145247 Nashed Jul 2005 A1
20050160532 Froelich Jul 2005 A1
20050193493 Gabbay Sep 2005 A1
20060032500 Ghiron et al. Feb 2006 A1
20060042631 Martin et al. Mar 2006 A1
20060118117 Berthon-Jones et al. Jun 2006 A1
20060124131 Chandran et al. Jun 2006 A1
20060168730 Menkedick et al. Aug 2006 A1
20060174889 Noble Aug 2006 A1
20060231091 Camarillo Oct 2006 A1
20070062536 McAuley et al. Mar 2007 A1
20070113847 Acker et al. May 2007 A1
20070113856 Acker et al. May 2007 A1
20070267017 McAuley et al. Nov 2007 A1
20070271699 Sacchetti Nov 2007 A1
20070295335 Nashed Dec 2007 A1
20080053446 Sleeper et al. Mar 2008 A1
20080092898 Schneider et al. Apr 2008 A1
20080110464 Davidson et al. May 2008 A1
20080196715 Yamamori Aug 2008 A1
20080221470 Sather et al. Sep 2008 A1
20080230067 Kwok et al. Sep 2008 A1
20090069646 Yamamori et al. Mar 2009 A1
20090084385 Lang Apr 2009 A1
20090095301 Hitchcock Apr 2009 A1
20090114229 Frater et al. May 2009 A1
20090114230 Hernandez et al. May 2009 A1
20090133696 Remmers et al. May 2009 A1
20090159084 Sher et al. Jun 2009 A1
20090178680 Chang Jul 2009 A1
20090250061 Marasigan Oct 2009 A1
20090260628 Flynn Oct 2009 A1
20090301472 Kim Dec 2009 A1
20090320850 Wallnewitz et al. Dec 2009 A1
20100113955 Colman et al. May 2010 A1
20100122701 Gunaratnam et al. May 2010 A1
20100122705 Moenning, Jr. May 2010 A1
20100147313 Albrecht Jun 2010 A1
20100170513 Bowditch Jul 2010 A1
20100170516 Grane Jul 2010 A1
20100218316 Nissen et al. Sep 2010 A1
20100224199 Smith et al. Sep 2010 A1
20100275919 Sung Nov 2010 A1
20100313891 Veliss et al. Dec 2010 A1
20110054366 Smith et al. Mar 2011 A1
20110072582 Patterson et al. Mar 2011 A1
20110083670 Walacavage Apr 2011 A1
20110092930 Poorman Apr 2011 A1
20110108035 Samaniego May 2011 A1
20110114099 Goldstein May 2011 A1
20110155136 Lee Jun 2011 A1
20110173750 Lehmann Jul 2011 A1
20110186050 Daly Aug 2011 A1
20110214674 Ging et al. Sep 2011 A1
20110253150 King Oct 2011 A1
20110265796 Amarasinghe et al. Nov 2011 A1
20110290253 McAuley et al. Dec 2011 A1
20110315143 Frater Dec 2011 A1
20120080035 Guney et al. Apr 2012 A1
20120111330 Gartner May 2012 A1
20120144588 Heimbrock et al. Jun 2012 A1
20120180220 Popitz Jul 2012 A1
20120222680 Eves et al. Sep 2012 A1
20120227736 Bowsher Sep 2012 A1
20120234326 Mazzone et al. Sep 2012 A1
20120247475 Hernandez et al. Oct 2012 A1
20120271187 McNeill Oct 2012 A1
20120285455 Varga et al. Nov 2012 A1
20120285466 Pierro et al. Nov 2012 A1
20120305001 Tatkov Dec 2012 A1
20130014760 Matula, Jr. et al. Jan 2013 A1
20130019870 Collazo et al. Jan 2013 A1
20130023729 Vazales Jan 2013 A1
20130060157 Beard Mar 2013 A1
20130109992 Guyette May 2013 A1
20130146060 Ho et al. Jun 2013 A1
20130186413 Haines et al. Jul 2013 A1
20130190643 Brambilla Jul 2013 A1
20130192601 Reischl et al. Aug 2013 A1
20130192602 Leibitzki et al. Aug 2013 A1
20130199537 Formica et al. Aug 2013 A1
20130319417 Weinman Dec 2013 A1
20140018691 McNeill Jan 2014 A1
20140076311 Darab Mar 2014 A1
20140083425 Moenning, Jr. Mar 2014 A1
20140144448 Eifler May 2014 A1
20140158135 Shyong Jun 2014 A1
20140158136 Romagnoli et al. Jun 2014 A1
20140215687 Andrews Aug 2014 A1
20140243600 Eisenberger Aug 2014 A1
20140245537 Allen Sep 2014 A1
20140251333 Burk Sep 2014 A1
20140326246 Chodkowski et al. Nov 2014 A1
20140352072 Holladay Dec 2014 A1
20140360504 Kwok Dec 2014 A1
20150047647 Winer Feb 2015 A1
20150059759 Frater et al. Mar 2015 A1
20150144140 Eury May 2015 A1
20150217075 Nair Aug 2015 A1
20150238716 Budhiraja et al. Aug 2015 A1
20150250970 Bowsher Sep 2015 A1
20150250971 Bachelder et al. Sep 2015 A1
20150273170 Bachelder et al. Oct 2015 A1
20150273171 Sullivan et al. Oct 2015 A1
20150335852 Miller Nov 2015 A1
20160015923 Chodkowski et al. Jan 2016 A1
20160022944 Chodkowski et al. Jan 2016 A1
20160038709 Beard Feb 2016 A1
20160067441 Bearne et al. Mar 2016 A1
20160184540 Kokko Jun 2016 A1
20160213281 Eckerbom Jul 2016 A1
20160213871 Darab Jul 2016 A1
20160279368 Isenberg Sep 2016 A1
20180078726 Barraclough Mar 2018 A1
Foreign Referenced Citations (38)
Number Date Country
202478364 Oct 2012 CN
202505937 Oct 2012 CN
103153378 Jun 2013 CN
203416833 Feb 2014 CN
205073472 Mar 2016 CN
19831022 Jan 2000 DE
19947722 Apr 2001 DE
2433666 Mar 2012 EP
3307367 Apr 2018 EP
187863 Nov 1922 GB
2209950 Jun 1989 GB
2456136 Jul 2009 GB
S4416955 Jul 1969 JP
H294566 Jul 1990 JP
2003502117 Jan 2003 JP
2004321721 Nov 2004 JP
2005318975 Nov 2005 JP
2008511399 Apr 2008 JP
2009172347 Aug 2009 JP
2013538631 Oct 2013 JP
WO-2010059592 May 2010 WO
WO-2012094730 Jul 2012 WO
WO-2012106373 Aug 2012 WO
WO-2013036839 Mar 2013 WO
WO-2013064950 May 2013 WO
WO-2013142909 Oct 2013 WO
WO-2014038959 Mar 2014 WO
WO-2014077708 May 2014 WO
WO-2014210606 Dec 2014 WO
WO-2015063283 May 2015 WO
WO-2015131262 Sep 2015 WO
WO-2015147947 Oct 2015 WO
WO-2015187995 Dec 2015 WO
WO-2016007749 Jan 2016 WO
WO-2016028522 Feb 2016 WO
WO-2016097948 Jun 2016 WO
WO-2016118922 Jul 2016 WO
WO-2016201358 Dec 2016 WO
Non-Patent Literature Citations (122)
Entry
Australian Certificate of Registration issued in application No. 201512961, dated Aug. 7, 2015, 5 pages.
Australian Certificate of Registration issued in application No. 201512962, dated Aug. 11, 2015, 5 pages.
Australian Examination Report No. 1 for Application No. 2015269351, dated Mar. 8, 2019, 5 pages.
Australian Office Action for Application No. 2017328060, dated Sep. 15, 2021, 4 pages.
Australian Office Action for Application No. 2020201805, dated Aug. 3, 2020, 3 pages.
Ball et al., “Performance comparison of two anaesthetic facemasks”, Anaesth Intensive Care, Apr. 2007, vol. 35, Issue 2, 226-9 (abstract only), 2 pages.
Canadian Office Action for Application No. 2951226, dated Jun. 22, 2021, 5 pages.
Canadian Office Action issued in Application No. 162891, dated Apr. 5, 2016, 1 page.
Canadian Office Action issued in Application No. 162891, dated Nov. 10, 2015, 7 pages.
Chinese Notification of Grant for Application No. 201530191921.6, dated Feb. 15, 2016, 12 pages.
Chinese Office Action (w/translation) for Application No. 201480042735.9, dated Apr. 5, 2017, 18 pages.
Chinese Office Action for Application No. 201480042735.9, dated Nov. 6, 2017, 21 pages.
Chinese Office Action for Application No. 201580029981.5, dated Apr. 15, 2019, 12 pages.
Chinese Office Action for Application No. 201580029981.5, dated Oct. 8, 2019, 14 pages.
Chinese Office Action for Application No. 201580029981.5, dated Sep. 5, 2018, 14 pages.
Chinese Office Action for Application No. 201730161613.8, dated Aug. 7, 2017, 2 pages.
Chinese Office Action for Application No. 201730161613.8, dated Sep. 19, 2017, 11 pages.
Chinese Office Action for Application No. 201780070064.0, dated Apr. 8, 2021, 17 pages including translation.
Chinese Office Action for Application No. 201780070064.0, dated Oct. 9, 2021, 18 pages including translation.
CPAP product description, http://www.cpap.com/productpage/pr-amara-full-face-cpap-mask-gel-silicone.html, downloaded Jul. 28, 2016, 11 pages.
CPAPXCHANGE product image, http://www.cpapexchange.com/cpap-masks-bipap-masks/bluegel-full-cushion-comfortgel-cpap-bipap-masks.jpg, downloaded Jul. 28, 2016, 1 page.
DirectHome Medical product description, http://www.directhomemedical.com/profilelite-gel-cpap-mask-philipsrespironics.html#.VwXLIPkrLIU, downloaded Jul. 28, 2016, 6 pages.
English Translation of Japanese Office Action for Application No. 2016-005262, dated Jun. 30, 2016, 1 page.
English Translation of Japanese Office Action for Application No. 2016-005263, dated Jun. 30, 2016, 1 page.
European Office Action for Application No. 003933217-0001, dated May 16, 2017, 2 pages.
European Partial Supplementary European Search Report for Application No. 14818563.0, dated Jan. 30, 2017, 6 pages.
Extended European Search Report for Application No. 14818563.0, dated May 3, 2017, 12 pages.
Extended European Search Report for Application No. 15803670.7, dated Oct. 24, 2018, 12 pages.
Extended European Search Report for Application No. 15833101.7, dated Jul. 3, 2018, 13 pages.
Extended European Search Report for Application No. 17851288.5, dated Apr. 22, 2020, 14 pages.
Extended European Search Report for Application No. 20165643.6, dated Jun. 24, 2020, 7 pages.
Indian Office Action for Indian Design Patent Application No. 272704, dated Aug. 28, 2015, 13 pages.
InnoMed Technologies Sylent Mask product description, http://innomedinc.com/sylent-ne-disposable-nasal-mask/, downloaded Jul. 28, 2016, 2 pages.
InnoMed Technologies, Hybrid Mask product description, http://innomedinc.com/hybrid/, downloaded Jul. 28, 2016, 4 pages.
International Preliminary Report on Patentability for Application No. PCT/US2014/044934, dated Jan. 7, 2016, 12 pages.
International Preliminary Report on Patentability for Application No. PCT/US2015/021323, dated Oct. 6, 2016, 8 pages.
International Preliminary Report on Patentability for Application No. PCT/US2015/044341, dated Mar. 2, 2017, 10 pages.
International Preliminary Report on Patentability for Application No. PCT/US2016/037070, dated Dec. 12, 2017, 7 pages.
International Preliminary Report on Patentability for Application No. PCT/US2015/034277, dated Dec. 15, 2016, 11 pages.
International Search Report and Written Opinion for Application No. PCT/US14/44934, dated Jan. 2, 2015, 16 pages.
International Search Report and Written Opinion for Application No. PCT/US2015/044341, dated Jan. 7, 2016, 13 pages.
International Search Report and Written Opinion for Application No. PCT/US2015/34277, dated Nov. 23, 2015, 16 pages.
International Search Report and Written Opinion for Application No. PCT/US2016/037070, dated Nov. 10, 2016, 11 pages.
International Search Report and Written Opinion for Application No. PCT/US2017/048046, dated Nov. 6, 2017, 11 pages.
Invitation to Pay Additional Fees for Application No. PCT/US14/44934, dated Oct. 24, 2014, 3 pages.
Invitation to Pay Additional Fees for Application No. PCT/US15/44341, dated Oct. 21, 2015, 2 pages.
Israeli Notice of Allowance for Application No. 57056 (w/translation of relevant portions), dated Nov. 1, 2015, 3 pages.
Israeli Notice of Allowance for Application No. 57056 (no translation), dated May 29, 2016, 1 page.
Israeli Office Action for Application No. 57850 (w/translation of relevant portions), dated Feb. 14, 2016, 3 pages.
Israeli Office Action for Application No. 58250 (w/translation of relevant portions), dated Jun. 29, 2016, 2 pages.
Israeli Office Action issued in application No. 58250 (w/translation of relevant portions), dated Jul. 18, 2016, 3 pages.
Japanese Decision for Registration (w/translation) for Application No. 2016-006559, dated May 12, 2017, 2 pages.
Japanese Decision for Registration (w/translation) for Application No. 2016-006560, dated May 12, 2017, 2 pages.
Japanese Decision for Registration for Application No. 2016-005263, dated Dec. 22, 2017, 4 pages.
Japanese Decision for Registration for Application No. 2017-009813, dated Oct. 6, 2017, 2 pages.
Japanese Office Action (w/translation) for Application No. 2016-005262, dated Apr. 28, 2017, 7 pages.
Japanese Office Action (w/translation) for Application No. 2016-005263, dated Apr. 28, 2017, 7 pages.
Japanese Office Action (w/translation) for Application No. 2016-006559, dated Sep. 2, 2016, 3 pages.
Japanese Office Action (w/translation) for Application No. 2016-006560, dated Sep. 2, 2016, 3 pages.
Japanese Office Action for Application No. 2015-013148, dated Dec. 18, 2015, 3 pages.
Japanese Office Action for Application No. 2016-005262, dated Dec. 22, 2017, 4 pages.
Japanese Office Action for Application No. 2016-571111, dated Jun. 11, 2019, 10 pages.
Japanese Office Action for Application No. 2017-009813, dated Jul. 28, 2017, 3 pages.
Japanese Office Action for Application No. 2017-509724, dated Jul. 24, 2018, 12 pages.
Japanese Office Action for Application No. 2019-515265, dated Nov. 24, 2021, 6 pages including translation.
Japanese Office Action for Application No. 2020098813, dated Jun. 22, 2021, 9 pages including translation.
Korean Design of Registration for Application No. 30-2015-0029561, M002 (w/translation), dated Jul. 27, 2016, 3 pages.
Korean Notice of Design of Registration for Application No. 30-2015-0029561, M001 (w/translation), dated Jun. 29, 2016, 3 pages.
Korean Office Action for Application No. 30-2015-0029561, M0001, dated Jun. 9, 2016, 16 pages.
Korean Office Action for Application No. 30-2015-0029561, M001 (w/translation), dated Dec. 24, 2015, 12 pages.
Korean Office Action for Application No. 30-2015-0029561, M001, dated May 23, 2016, 2 pages.
Korean Office Action for Application No. 30-2015-0029561, M002 (w/translation), dated Dec. 24, 2015, 7 pages.
Korean Office Action for Application No. 30-2015-0029561, M002 (w/translation), dated May 23, 2016, 6 pages.
Liang, Yafen et al., “Nasal Ventilation is More Effective than Combined Oral-Nasal Ventilation during Induction of General Anesthesia in Adult Subjects”, Anesthesiology 2008, vol. 108, No. 6, Jun. 2008, pp. 998-1003.
Mexican Office Action for Application No. MX/a/2016/015858, dated Feb. 25, 2021, 9 pages including machine translation.
New Zealand Office Action for Application No. 764985, dated Sep. 20, 2021, 4 pages.
Notice of Allowance (corrected) for U.S. Appl. No. 15/288,973, dated Feb. 10, 2017, 16 pages.
Notice of Allowance (corrected) for U.S. Appl. No. 15/288,973, dated Mar. 10, 2017, 9 pages.
Notice of Allowance (corrected) for U.S. Appl. No. 15/288,973, dated Mar. 24, 2017, 9 pages.
Notice of Allowance for U.S. Appl. No. 15/288,973, dated Feb. 1, 2017, 25 pages.
Notice of Decision of Registration for Design for Korean Design Application No. 30-20016-0014111, dated Dec. 13, 2016, 3 pages.
Office Action for U.S. Appl. No. 29/520,420, dated Aug. 11, 2016, 18 pages.
Office Action for U.S. Appl. No. 29/530,124, dated Aug. 12, 2016, 17 pages.
Office Action for U.S. Appl. No. 15/272,074, dated Apr. 19, 2017, 54 pages.
Office Action for U.S. Appl. No. 15/272,074, dated Jul. 31, 2017, 34 pages.
Office Action for U.S. Appl. No. 15/272,074, dated Sep. 13, 2017, 5 pages.
Office Action for U.S. Appl. No. 15/272,160, dated Apr. 24, 2017, 39 pages.
Office Action for U.S. Appl. No. 15/272,160, dated Dec. 15, 2017, 34 pages.
Office Action for U.S. Appl. No. 15/272,160, dated Jan. 4, 2017, 31 pages.
Office Action for U.S. Appl. No. 15/272,190, dated Dec. 28, 2017, 22 pages.
Office Action for U.S. Appl. No. 15/272,190, dated Jan. 30, 2017, 32 pages.
Office Action for U.S. Appl. No. 15/272,190, dated Jun. 21, 2017, 7 pages.
Office Action for U.S. Appl. No. 15/272,190, dated May 23, 2017, 36 pages.
Office Action for U.S. Appl. No. 15/288,973, dated Dec. 14, 2016, 21 pages.
Office Action for U.S. Appl. No. 29/520,420, dated Apr. 7, 2017, 3 pages.
Office Action for U.S. Appl. No. 29/520,420, dated Dec. 8, 2017, 5 pages.
Office Action for U.S. Appl. No. 29/520,420, dated Feb. 24, 2017, 14 pages.
Office Action for U.S. Appl. No. 29/520,420, dated Jun. 15, 2017, 12 pages.
Office Action for U.S. Appl. No. 29/530,124, dated Apr. 19, 2017, 6 pages.
Office Action for U.S. Appl. No. 29/530,124, dated Aug. 30, 2017, 3 pages.
Office Action for U.S. Appl. No. 29/530,124, dated Aug. 9, 2017, 11 pages.
Office Action for U.S. Appl. No. 29/530,124, dated Feb. 28, 2017, 16 pages.
Office Action for U.S. Appl. No. 29/530,124, dated Jun. 21, 2017, 14 pages.
Office Action for U.S. Appl. No. 29/530,124, dated Nov. 29, 2017, 31 pages.
Partial Supplementary European Search Report for Application No. 16808466.3, dated Jan. 22, 2019, 14 pages.
Singapore Invitation to Respond to Written Opinion for Application No. 11201610048P, dated Sep. 19, 2017, 16 pages.
Singapore Invitation to Respond to Written Opinion for Application No. 11201701253U, dated Nov. 8, 2017, 12 pages.
Singapore Search Report for Application No. 11201510589T, dated Jan. 31, 2017, 11 pages.
Sleep Medicine Solutions product description, Http://sleepmedicinesolutions.net.au/cpap-spare-parts/26-fisher-paykel-zest-foams.html, downloaded Jul. 28, 2016, 2 pages.
Sleepnet homepage, https://web.archive.org/web/20111021122613/http://www.sleepnetmasks.com/, downloaded Jul. 28, 2016, 4 pages.
European Office Action for Application No. 20165643.6, dated Apr. 25, 2022, 3 pages.
Japanese Office Action for Application No. 2022-053950, dated Oct. 21, 2022, 4 pages, including translation.
Australian Office Action for Application No. 2017328060, dated May 10, 2022, 2 pages.
Extended European Search Report for Application No. 21206190.7, dated Mar. 10, 2022, 11 pages.
Official Action for Australia Patent Application No. 2022275401, dated Nov. 21, 2023 3 pages.
Official Action with English Translation for Brazil Patent Application No. BR112019004967-3, dated Mar. 2, 2023 5 pages.
Official Action for Canada Patent Application No. 3,036,797, dated Aug. 7, 2023 3 pages.
Intention to Grant for European Patent Application No. 21206190.7, dated Oct. 17, 2023 35 pages.
Decision to Grant with Machine Translation for Japan Patent Application No. 2023-029793, dated Aug. 29, 2023 2 pages.
Official Action for U.S. Appl. No. 16/333,215, dated May 20, 2021 24 pages.
Notice of Allowance for U.S. Appl. No. 16/333,215, dated Sep. 13, 2021 9 pages.
Intention to Grant for European Patent Application No. 21206190.7, dated Mar. 6, 2024 35 pages.
Related Publications (1)
Number Date Country
20220126047 A1 Apr 2022 US
Provisional Applications (4)
Number Date Country
62510192 May 2017 US
62467808 Mar 2017 US
62425371 Nov 2016 US
62394405 Sep 2016 US
Continuations (1)
Number Date Country
Parent 16333215 US
Child 17572494 US